Figure 1:
Figure 2:
NLR pre- and post-treatment for grouped by stades, gradus and treatment fractions_
| Staging | NLR | |
|---|---|---|
| Pre-treatment | Post-treatment | |
| I | 1.62 | 2.63 |
| IA | 1.95 | 2.48 |
| II | 1.92 | 4.11 |
| IIA | 2.93 | 3.39 |
| IIB | 1.58 | 2.67 |
| III | 2.10 | 1.36 |
| IIIA | 2.01 | 3.03 |
| IIIB | 1.56 | 1.80 |
| IIIC | 1.90 | 2.25 |
Descriptive Statistics – Patient Characteristics_
| N = 56 | % | |
|---|---|---|
| Median age (years) | 53.42 | (32–75) |
| Sex | ||
| Female | 56 | 100 |
| Male | 0 | 0 |
| Age group | ||
| >40 | 51 | 91.07 |
| ≤40 | 5 | 8.93 |
| Comorbidity | ||
| No | 12 | 21.43 |
| Diabetes | 5 | 8.93 |
| Hypertension | 29 | 51.79 |
| Diabetes + hypertension | 10 | 17.86 |
| Stage | ||
| I | 2 | 3.57 |
| IA | 3 | 5.36 |
| II | 8 | 14.29 |
| IIA | 6 | 10.71 |
| IIB | 13 | 23.21 |
| III | 1 | 1.79 |
| IIIA | 15 | 26.79 |
| IIIB | 2 | 3.57 |
| IIIC | 6 | 10.71 |
| Histopathologic type | ||
| Ductal carcinoma | 31 | 55.36 |
| Non-ductal carcinoma | 25 | 44.64 |
| Grade | ||
| Grade 1 | 4 | 7.14 |
| Grade 2 | 30 | 53.57 |
| Grade 3 | 22 | 39.29 |
| Chemotherapy cycle | ||
| Four cycles | 6 | 10.71 |
| Six cycles | 11 | 19.64 |
| Eight cycle | 39 | 69.64 |
| Radiotherapy fractions | ||
| 25 | 29 | 51.79 |
| 28 | 20 | 35.71 |
| 30 | 7 | 12.50 |